Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3152W HIGH $8.10
Volume
5.51 M
Value Traded
44.36 M
Short % Float
0.99%
Days to Cover
1.0
0%Week
+0.88%1 Month
+183.45%3 Month
+215.69%6 Month
-32.92%5 Year
-32.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
383.88 M
EPS (TTM)
-2.06
P/E Ratio
-
Ent. Value
329.33 M
Total Shares
47.69 M
Float Shares
31.96 M
Insiders
32.98%
Institutions
51.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VIGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Vigil Neuroscience, Inc.
Past FDA Catalysts and PDUFA Decisions
How VIGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | VG-3927 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VG-3927 Small moleculeCompletedNCT06343636 | Alzheimer Disease | Phase 1 | COMPLETED | 115 | Jan 10, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every VIGL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| iluzanebart Accelerated | adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) | Phase 2 | 2025-06-04 | no beneficial effects on biomarker or clinical efficacy endpointsRead More | Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Budd Haeberlein Samantha L.Director | Buy | 12,000 12,000 held | $1.71 | 12/19/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in VIGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 1.6 % | 7.95 M | 1.00 M |
Ownership Trends
VIGL Short Interest
Shares sold short, counted twice a month.
0.99%
Short % of Float
of tradable shares sold short
567.7K
Shares Sold Short
+26.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
912.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VIGL ranks across every disease it competes in
Competitive Position is a premium feature
See how VIGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVIGL News
About Vigil Neuroscience, Inc.
Founded2022
BIOPHARMAWATCH ELITE PLUS
Trade the next VIGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime